Audio Journal of Oncology Podcast
Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy
10 Jun 2025
An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota. CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon cancer whose tumors tested positive for deficient mismatch repair. At the American Society of Clinical Oncology 2025 Annual Meeting Frank Sinicrope reported findings from the phase three ATOMIC trial in which the immune checkpoint inhibitor atezolizumab was added to adjuvant chemotherapy after resection. He discussed the study results with Audio Journal of Oncology correspondent Peter Goodwin: INTERVIEW: Frank A Sinicrope MD, Mayo Clinic, Rochester, Minnesota ASCO Abstract LBA1: “Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC)”
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
3ª PARTE | 17 DIC 2025 | EL PARTIDAZO DE COPE
01 Jan 1970
El Partidazo de COPE
Buchladen: Tipps für Weihnachten
20 Dec 2025
eat.READ.sleep. Bücher für dich
BOJ alza 25pb decennale sopra 2%, Oracle vola con accordo Tik Tok, 90 mld eurobond per Ucraina | Morning Finance
19 Dec 2025
Black Box - La scatola nera della finanza
365. The BEST advice for managing ADHD in your 20s ft. Chris Wang
19 Dec 2025
The Psychology of your 20s
LVST 19 de diciembre de 2025
19 Dec 2025
La Venganza Será Terrible (oficial)
Cuando la Ciencia Ficción Explicó el Mundo que Hoy Vivimos
19 Dec 2025
El Podcast de Marc Vidal